Swedish Orphan Biovitrum AB (publ)

June 30, 2011 02:38 ET

Change of number of shares and votes in Sobi

STOCKHOLM, SWEDEN--(Marketwire - Jun 30, 2011) - As a result of the rights issue of common shares recently implemented by Swedish Orphan Biovitrum, the number of shares and votes in the company has changed during June 2011 as follows.

The number of shares has increased by 53,045,319 common shares and the total number of shares in the company as of June 30, 2011 amounts to 267,295,132 shares, of which 265,226,598 common shares and 2,068,534 class C shares*. The total number of votes in the company has increased by 53,045,319 and amounts to in total 265,433,451.4 votes. The company's share capital as of June 30, 2011 amounts to approximately SEK 146,663,999.7.

About Swedish Orphan Biovitrum (Sobi)

Sobi is a leading European specialty pharmaceutical company focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on June 30, 2011 at 8.30 CET.

*) All C-shares are held by Sobi.

Sobi Press Release June 30, 2011 - pdf format: http://hugin.info/134557/R/1527142/462898.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE


Contact Information

  • For additional information, please contact:
    Asa Stenqvist
    VP Communications and Investor Relations
    Tel.: +46 8 697 21 88